Circadian Disruption Reshapes Tumor Immunity, Potentially Driving Cancer Spread

Researchers have long noticed that people who work night shifts or cross time zones frequently seem to get cancer more often, and when they do, it spreads faster. A new review synthesizes what science now understands about why: the body's internal clock doesn't just regulate sleep and wakefulness. It orchestrates the immune system's ability to fight tumors, controls how blood vessels form around cancer cells, and determines whether tumor cells can slip into the bloodstream and establish themselves elsewhere. The International Agency for Research on Cancer has classified circadian disruption—caused by light exposure at night, shift work, chronic jet lag, or genetic mutations in clock genes—as a Group 2A carcinogen, the same category as red meat. The link is strongest for breast and colorectal cancers.

The review, published in Cancer Biology & Medicine and led by researchers at Shanghai Geriatric Medical Center, Zhongshan Hospital, Fudan University, and Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, maps how clock genes reshape the tumor microenvironment at each stage of metastasis. At the molecular level, the body's circadian system relies on a feedback loop involving proteins with names like BMAL1, CLOCK, PER, and CRY. These proteins don't just tick away in the brain. They're active in tumors themselves, in immune cells, in the blood vessel walls, and in the tissue surrounding cancer cells. The same clock gene can either restrain cancer spread or accelerate it, depending on the tumor type, the stage of disease, and the time of day—a finding that upends the idea that circadian biology is simply a risk factor to avoid.

At the invasive edge of a tumor, clock genes influence whether cancer cells undergo epithelial-to-mesenchymal transition, a process that makes them more mobile. BMAL1, one of the core clock proteins, can suppress migration in some tumors but promote it in others by ramping up production of matrix metalloproteinases, enzymes that break down tissue barriers. PER2, another clock protein, normally restrains the genetic programs that drive this transition. As tumor cells prepare to enter blood vessels—a step called intravasation—circadian disruption shifts the behavior of immune cells called macrophages and alters the balance of signaling molecules like transforming growth factor-beta and interleukin-6, creating an environment where tumor cells can slip through vessel walls more easily. Once in circulation, the number of tumor cells in the blood and the activity of platelets that help them survive fluctuate over a 24-hour cycle. The adhesion molecules on blood vessel walls that determine where tumor cells can stick and exit the circulation—ICAM-1 and VCAM-1—also show rhythmic expression, meaning the windows for extravasation, the process of leaving the bloodstream, open and close on a schedule.

The review highlights how circadian clocks control multiple pathways that suppress immune attack on tumors. Myeloid-derived suppressor cells, which dampen natural killer cell activity, respond to clock signals. Regulatory T cells and cancer-associated fibroblasts, both of which help tumors evade the immune system, are clock-regulated. Angiogenesis, the formation of new blood vessels that feed tumors, is driven by vascular endothelial growth factor, a protein whose production follows circadian rhythms. Even the exosomes—tiny vesicles that tumors release to communicate with distant tissues and prepare them for metastatic colonization—are secreted according to a circadian schedule controlled by the protein RAB27A.

The authors emphasize that the field is moving beyond simply documenting that circadian disruption increases cancer risk. The real question now is when and where metastatic niches become permissive—vulnerable to invasion. Because the same clock component can either restrain or accelerate spread depending on context, future research must combine time-series single-cell RNA sequencing, circadian proteomics, and intravital imaging to map these rhythms in real time. This work could identify narrow windows when tumors are most vulnerable to treatment, and it might explain why some patients respond differently to immunotherapy or chemotherapy depending on when they receive it.

If these findings hold up in patients, they could transform cancer treatment through chronotherapy—timing chemotherapy, radiotherapy, or immunotherapy to periods when tumors and their microenvironment are most susceptible. Clock-modulating drugs, including compounds that target BMAL1 and REV-ERB agonists, show early promise in preclinical studies, though their safety and specificity require rigorous testing. The review calls for standardized reporting in circadian cancer research: the time of day samples were collected, the light-dark cycles patients experienced, their sex and age, and time-aware statistical methods. Clinical trials may need to record not just what treatment patients received, but when they received it and their individual chronotype—whether they're naturally early risers or night owls. Such steps could transform circadian biology from a descriptive risk factor into a practical tool for precision oncology. For patients, this could mean smarter treatment schedules rather than new drugs alone.